Indivior (NASDAQ:INDV - Get Free Report) is expected to be posting its Q1 2025 quarterly earnings results before the market opens on Thursday, April 24th. Analysts expect Indivior to post earnings of $0.22 per share and revenue of $240.13 million for the quarter. Indivior has set its FY 2025 guidance at EPS.
Indivior (NASDAQ:INDV - Get Free Report) last posted its quarterly earnings results on Thursday, February 20th. The company reported $0.32 earnings per share (EPS) for the quarter, hitting the consensus estimate of $0.32. Indivior had a negative return on equity of 241.73% and a negative net margin of 3.96%. The firm had revenue of $298.00 million during the quarter, compared to analyst estimates of $262.35 million. On average, analysts expect Indivior to post $1 EPS for the current fiscal year and $2 EPS for the next fiscal year.
Indivior Stock Performance
INDV stock remained flat at $8.81 during trading on Tuesday. 1,768,799 shares of the company traded hands, compared to its average volume of 954,830. The stock has a market capitalization of $1.21 billion, a PE ratio of -25.17 and a beta of 0.93. Indivior has a one year low of $7.33 and a one year high of $19.13. The stock has a 50-day simple moving average of $9.46 and a 200 day simple moving average of $10.31.
Wall Street Analyst Weigh In
Several research firms have recently weighed in on INDV. Rodman & Renshaw began coverage on Indivior in a research note on Tuesday, January 28th. They issued a "buy" rating and a $16.00 price target for the company. Piper Sandler decreased their target price on Indivior from $16.00 to $13.00 and set an "overweight" rating for the company in a research report on Thursday, March 6th. Finally, RODMAN&RENSHAW upgraded shares of Indivior to a "strong-buy" rating in a research note on Tuesday, January 28th.
Read Our Latest Analysis on INDV
About Indivior
(
Get Free Report)
Indivior PLC, together with its subsidiaries, engages in the development, manufacture, and sale of buprenorphine-based prescription drugs for the treatment of opioid dependence and co-occurring disorders in the United States, the United Kingdom, and internationally. The company develops medicines to treat substance use disorders, serious mental illnesses, and opioid overdose.
Featured Articles
Before you consider Indivior, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Indivior wasn't on the list.
While Indivior currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
